Hubei Vanz Pharm Co.,ltd.


warrantable quality,trustable service!

About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsActive Pharmaceutical Ingredient

White Nootropics Powder 99% Purity Vinpocetine powder CAS 42971-09-5

I'm Online Chat Now
China Wuhan Vanz Pharm Inc. certification
China Wuhan Vanz Pharm Inc. certification
I am very happy to cooperate with your company for nearly three years, thank you very attentive service, thank you for the excellent product quality.

—— Stephnie

You always have very fast delivery, very happy to cooperate with you. Thank you.

—— John

Very pleased to become your customer, and very happy for our cooperation, hope to be your long-term parter.

—— Sara

we received the package, very fast, the quality is very good, will continue to buy your products.

—— Luice

I have emailed you a couple times and they get returned as undeliverable. Yes. I am happy with the powders. thank you.

—— Bryan

White Nootropics Powder 99% Purity Vinpocetine powder CAS 42971-09-5

White Nootropics Powder 99% Purity Vinpocetine powder CAS 42971-09-5
White Nootropics Powder 99% Purity Vinpocetine powder CAS 42971-09-5 White Nootropics Powder 99% Purity Vinpocetine powder CAS 42971-09-5

Large Image :  White Nootropics Powder 99% Purity Vinpocetine powder CAS 42971-09-5 Get Best Price

Product Details:

Place of Origin: China
Brand Name: VANZ
Model Number: 42971-09-5

Payment & Shipping Terms:

Minimum Order Quantity: 100g
Price: 1-10 USD per gram
Packaging Details: 100g, 1kg alunimum foil bags or 25kg drum
Supply Ability: 10kg per month
Detailed Product Description
Appearance: White Powder Synonyms: -
CAS: 42971-09-5 Purity: 99%min
MF: C22H26N2O2 MW: 369.341
High Light:

pharmaceutical active ingredients


active pharma ingredients

Nootropics Powder 99% Purity Vinpocetine powder CAS: 42971-09-5


Common Name(s): Vinpocetine , Cavinton , apovincaminic acid kavinton



The scientific literature contains numerous studies and investigations on the pharmacological and biochemical actions of vinpocetine, including antioxidant effects, menopause, antiulcer activity, and phosphodiesterase-1 inhibition. Vinpocetine is best known for its neuroprotective effects. However, there are limited clinical studies to support the use of vinpocetine for many of these potential uses.



Follow suggested manufacturers' product guidelines. Most clinical studies used vinpocetine 10 mg 3 times daily, orally or parenterally.




The drug should not be used in patients with severe, general, cerebral hypertensive crises, or in elderly or senile patients with acute cardio-cerebral or cerebro-cardiac syndrome, postinfarction cardiosclerosis, or marked disorders of heart rhythm.




Avoid use during pregnancy and lactation because of lack of clinical studies.



Caution is warranted in patients on blood-thinning medications because vinpocetine decreases platelet aggregation. In 1 study, bioavailability increased 60% to 100% when vinpocetine was taken with food.


Adverse Reactions

One review article documents patients reporting flushing, rashes, and minor GI problems.


Basic information


Name Ibrutinib
CAS 936563-96-1
Appearance white powder
MF C25H24N6O2
MW 440.5
Purity 99%min


Mechanism of action

Vinpocetine has been shown to selectively inhibit voltage-sensitive Na+ channels, resulting in a dose-dependent decrease in evoked extracellular Ca++ ions in striatal nerve endings. The Na+ channel inhibiting properties of vinpocetine are thought to contribute to a general neuroprotective effect through blockade of excitotoxicity and attenuation of neuronal damage induced by cerebral ischemia/reperfusion.


Vinpocetine is also a phosphodiesterase (PDE) type-1 inhibitor, (with an IC50 of approximately 10−5 M.) leading to increases in intracellular levels of cyclic guanosine 3'5'-monophosphate (cGMP), an action that causes the vasorelaxant effects of vinpocetine on cerebral smooth muscle tissue.

Independent of vinpocetine's action on PDE, vinpocetine inhibits IKK preventing IκB degradation and the following translocation of NF-κB to the cell nucleus.


Increases in neuronal levels of DOPAC, a metabolic breakdown product of dopamine, have been shown to occur in striatal isolated nerve endings as a result of exposure to vinpocetine. Such an effect is consistent with the biogenic pharmacology of reserpine, a structural relative of vinpocetine.However, this effect tends to be reversible upon cessation of vinpocetine administration, with full remission typically occurring within 3–4 weeks.





White Nootropics Powder 99% Purity Vinpocetine powder CAS 42971-09-5 0




Contact Details
Wuhan Vanz Pharm Inc.

Contact Person: Ms. du

Tel: 86 13277095342

Fax: 86-27-84492310

Send your inquiry directly to us